Janus Henderson Group PLC Decreases Stock Holdings in Icon Plc $ICLR

Posted by Stanley Muller on Aug 6th, 2026

Janus Henderson Group PLC reduced its position in shares of Icon Plc (NASDAQ:ICLR – Free Report) by 66.9% in the first quarter, HoldingsChannel reports. The institutional investor owned 82,061 shares of the medical research company’s stock after selling 166,218 shares during the quarter. Janus Henderson Group PLC’s holdings in Icon were worth $9,081,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. WINTON GROUP Ltd bought a new position in shares of Icon during the second quarter valued at about $254,000. Daiwa Securities Group Inc. grew its stake in shares of Icon by 19.3% in the second quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock worth $4,094,000 after purchasing an additional 4,546 shares during the last quarter. Frontier Capital Management Co. LLC increased its holdings in Icon by 97.6% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock valued at $10,379,000 after purchasing an additional 35,253 shares during the period. Peapack Gladstone Financial Corp purchased a new position in Icon during the 2nd quarter valued at about $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Icon by 58.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock valued at $113,000 after purchasing an additional 289 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Stock Performance

Icon stock opened at $163.51 on Thursday. The stock’s 50 day simple moving average is $159.29 and its two-hundred day simple moving average is $134.80. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95. The stock has a market cap of $12.52 billion, a price-to-earnings ratio of 38.38, a PEG ratio of 6.55 and a beta of 1.21. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $203.91.

Icon (NASDAQ:ICLR – Get Free Report) last posted its earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, topping analysts’ consensus estimates of $2.55 by $0.01. The firm had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%.The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.26 EPS. As a group, analysts expect that Icon Plc will post 9.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on ICLR. Bank of America increased their price objective on Icon from $125.00 to $150.00 and gave the stock an “underperform” rating in a report on Thursday, June 25th. Zacks Research upgraded Icon from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. UBS Group set a $160.00 target price on Icon in a report on Wednesday, June 24th. TD Cowen lifted their price target on shares of Icon from $164.00 to $197.00 and gave the company a “buy” rating in a report on Thursday, June 25th. Finally, Citigroup lifted their price target on shares of Icon from $165.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $170.40.

Read Our Latest Analysis on Icon

Icon Company Profile

(Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.

Janus Henderson Group PLC Decreases Stock Holdings in Icon Plc $ICLR

Icon Stock Performance

Analysts Set New Price Targets

Icon Company Profile

See Also

You might be interested in: